Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines,

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of Merck's recently approved RSV antibody drug for infants 8 months or younger whose mothers did not receive a preventive shot during pregnancy.